Tags

Type your tag names separated by a space and hit enter

Double-blind trial of labetalol.
Br J Clin Pharmacol. 1976 Aug; 3(4 Suppl 3):737-41.BJ

Abstract

1 A new anti-hypertensive agent (labetalol) with alpha- and beta-adrenoreceptor-blocking properties has been assessed in 30 patients in a general practice. 2 Significant reduction in blood pressure and pulse rate occurred at a dose of 400 mg/d. A further significant reduction in blood pressure but not of pulse rate occurred at a dose of 800 mg/d. 3 After 4 weeks' treatment on the higher dose the mean fall in systolic and diastolic pressures compared with the pre-trial pressures was 36 and 24 mmHg, respectively. Side-effects were generally mild.

Links

FREE Publisher Full Text

Authors

Kane J
No affiliation info available
Gregg I
No affiliation info available
Richards DA
No affiliation info available

MeSH

AdultAgedBlood PressureClinical Trials as TopicDose-Response Relationship, DrugDrug EvaluationEthanolaminesFemaleHumansHypertensionLabetalolMaleMiddle AgedPulseTime Factors

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

791329

Citation

Kane, J, et al. "Double-blind Trial of Labetalol." British Journal of Clinical Pharmacology, vol. 3, no. 4 Suppl 3, 1976, pp. 737-41.
Kane J, Gregg I, Richards DA. Double-blind trial of labetalol. Br J Clin Pharmacol. 1976;3(4 Suppl 3):737-41.
Kane, J., Gregg, I., & Richards, D. A. (1976). Double-blind trial of labetalol. British Journal of Clinical Pharmacology, 3(4 Suppl 3), 737-41.
Kane J, Gregg I, Richards DA. Double-blind Trial of Labetalol. Br J Clin Pharmacol. 1976;3(4 Suppl 3):737-41. PubMed PMID: 791329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind trial of labetalol. AU - Kane,J, AU - Gregg,I, AU - Richards,D A, PY - 1976/8/1/pubmed PY - 1976/8/1/medline PY - 1976/8/1/entrez SP - 737 EP - 41 JF - British journal of clinical pharmacology JO - Br J Clin Pharmacol VL - 3 IS - 4 Suppl 3 N2 - 1 A new anti-hypertensive agent (labetalol) with alpha- and beta-adrenoreceptor-blocking properties has been assessed in 30 patients in a general practice. 2 Significant reduction in blood pressure and pulse rate occurred at a dose of 400 mg/d. A further significant reduction in blood pressure but not of pulse rate occurred at a dose of 800 mg/d. 3 After 4 weeks' treatment on the higher dose the mean fall in systolic and diastolic pressures compared with the pre-trial pressures was 36 and 24 mmHg, respectively. Side-effects were generally mild. SN - 0306-5251 UR - https://www.unboundmedicine.com/medline/citation/791329/Double_blind_trial_of_labetalol_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0306-5251&date=1976&volume=3&issue=4 Suppl 3&spage=737 DB - PRIME DP - Unbound Medicine ER -